Expert consensus on the clinical application of immunotherapy in breast cancer: 2024.

Transl Breast Cancer Res · 2024 · PMC11094404 · PMID 38751677

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

The phase III TORCHLIGHT study ( 27 ) from China showed toripalimab + nab-paclitaxel treatment group significantly prolonged PFS benefit of mTNBC patients in PD-L1-positive (CPS ≥1) and ITT populations, and there was also a significant trend of OS benefit.

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.